E

veryone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown of individuals or companies that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.

Winners:

Marathon Pharmaceuticals: You know what they say: Make lemonade out of lemons. After enduring intense political heat over the $89,000 price tag it slapped on a recently approved rare disease drug, Marathon unexpectedly sold the medicine. But the company stands to come out way ahead. Marathon gets $140 million, plus another $50 million milestone payment and royalties for a decades-old steroid. Meanwhile, the company reportedly bought old data that formed the bulk of its marketing application for less than $1 million and spent anywhere from $6 million to $60 million on additional pre-clinical studies, but probably closer to the low end. And Marathon declined to sell a voucher it was awarded by the FDA along with the approval, which can be worth about $125 million. Not a bad deal, eh?

This is a STAT Plus article and is only available to STAT Plus subscribers.
To read the full story, subscribe to STAT Plus or log in to your account.
Good news: your first 30 days are on us.

Sign up for Morning Rounds

A daily dose of health and medicine news — and a finalist for Digiday’s best email newsletter.

Recommended Stories